Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model by Lubna Noorani et al.
Noorani et al. Journal of Nanobiotechnology  (2015) 13:25 
DOI 10.1186/s12951-015-0082-8RESEARCH Open AccessAlbumin nanoparticles increase the anticancer
efficacy of albendazole in ovarian cancer
xenograft model
Lubna Noorani1,2, Martina Stenzel1, Roger Liang3, Mohammad H Pourgholami2 and David L Morris2*Abstract
Background: The poor prognosis of patients with drug resistant ovarian cancer and the lack of targeted therapy have
raised the need for alternative treatments. Albendazole (ABZ) is an anti-parasite compound capable of impairing
microtubule formation. We hypothesized that ABZ could be repurposed as a potential anti-angiogenic drug due to its
potent inhibition of vascular endothelial growth factor (VEGF) in ovarian cancer with ascites. However, the poor
aqueous solubility of ABZ limits its potential for cancer therapy. In this study, we have assembled ABZ with bovine
serum albumin into nanoparticles with a size range of 7–10 nm (BSA-ABZ) and 200–250 nm (Nab-ABZ). We further
examined the anticancer effects of ABZ carrying nanoparticles in ovarian cancer cells, in both in vitro and
in vivo models.
Results: Drug release studies demonstrated that about 93% of ABZ was released from BSA-ABZ 10 nm in comparison
to 83% from Nab-ABZ 200 nm at pH 7.4 in 8 days. In vitro cell proliferation studies showed that the BSA-ABZ 10 nm
exhibited the highest killing efficacy of ovarian cancer cells with surprisingly least toxicity to healthy ovarian epithelial
cells. Confocal microscopy and fluorescence activated cell sorting analysis (FACS) revealed more efficient internalization
of the BSA-ABZ 10 nm by cancer cells. For in vivo studies, we examined the tumor growth, ascites formation and the
expression of VEGF and secreted protein acidic and rich in cysteine (SPARC) in tumor samples and only VEGF in plasma
samples. The BSA-ABZ 10 nm reduced the tumor burden significantly (p < 0.02) at a much lower drug dose (10 μg/ml)
compare to free drug. Both formulations were capable of suppressing the ascites volume significantly (p < 0.05) and
reducing the number of ascites cells. The expression of VEGF and SPARC was also reduced, which indicates the
underlying therapeutic mechanism of the ABZ.
Conclusion: Our data suggest that the BSA-ABZ may hold promise for the treatment and control of progression of
ovarian cancer with ascites. However further studies are required to examine the efficacy of both the formulations in
aggressive models of recurrent ovarian cancer with respect to particle size and dosing parameters.
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Angiogenesis, the development of new capillaries from
existing vasculature, plays a key role in the pathogenesis of
metastases [1]. VEGF is important in tumor angiogenesis,
growth and metastasis [2,3], especially in ovarian cancers
and other solid tumors [4,5]. Substantial evidence suggests
that VEGF promotes the formation of ascites and is
present at a very high levels in ascites of patients with* Correspondence: David.Morris@unsw.edu.au
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unless otherwise stated.advanced ovarian cancer [6]. Patients suffering from recur-
rent ovarian cancer are known to be affected by malignant
ascites (accumulation of fluid containing cancer cells in
the abdomen) and develop intraperitoneal metastases,
thus leading to treatment failure. Current therapies that
exist for treating ascites are salt restriction, diuretics,
radioactive isotopes, paracentesis and shunt placement [7].
Recently, the anti-angiogenic agents, such as Bevacizumab
and the VEGF trap, have been shown to be effective in the
reduction of ascites [8]. VEGF trap had been combined
with Paclitaxel (PTX) to inhibit tumor and ascites and
prolong patient’s survival [9]. It has been shown that thel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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agents can significantly inhibit tumor growth and metasta-
sis and suppress the multidrug resistance (MDR) gene in
the tumor endothelium [10].
Albendazole (ABZ), Methyl [5-(Propylthio)-1-H-Benzi-
midazol-2Yl] Carbamate, is an anti-anthelminthic drug and
has been explored as a potential inhibitor of VEGF [11],
hypoxia inducible factor 1-α [12] and tumor angiogenesis
[13] over the past few years. The antitumor effect of ABZ
is related to its inhibition of tubulin polymerization and G2
M phase arrest of cell cycle [14,15]. In combination with
chemotherapeutics, ABZ shows superior anti-VEGF activ-
ity in a xenograft model of ovarian cancer [16]. ABZ also
improves the antitumor activity in combination with tubu-
lin binding agent 2- Methoxy estradiol [17]. In light of its
anticancer properties coupled with VEGF inhibition, we
hypothesized that ABZ could be repurposed as a new treat-
ment of ovarian cancer.
ABZ has very low aqueous solubility (0.55 μg/ml) and
bioavailability, which limits the potential use of ABZ in
cancer treatment. We perceived that the use of nano-
particle albumin bound (nab) technology in the drug
delivery system for ABZ may increase its solubility with
selective delivery to the tumors. Nab-technology is ba-
sically non-covalent association of hydrophobic drugs
with albumin and thus formation of nanoparticles that
are readily dispersible in water without any solvent or
surfactant. One of the most important features of the
albumin based drug delivery system is the enhanced
drug accumulation in tumor tissues due to the leaky
vasculature of the angiogenic vessels in solid tumor
[18]. The nab-based drug delivery system can also im-
prove drug uptake by exploiting the biological pathways
of albumin [19]. Abraxane® (nab-paclitaxel) was the
first nab-based oncology product approved for human
use by the FDA in 2005 [20,21]. Based on the concept of
albumin bound Paclitaxel (Abraxane®), we aimed to de-
velop a novel formulation with nanoparticle albumin
bound ABZ.
The current study aimed at exploring nab-technology
to solve the solubility problem of albendazole and re-
duce side effects by targeting tumor passively and in-
crease the efficacy. The study also focused on to pursue
a nano-sized drug delivery system (<50 nm) for better
absorption in the peritoneal cavity and compared the ef-
fect of particle sizes in in-vitro and in-vivo models of
ovarian cancer.
To achieve these, nanoparticles were prepared by opti-
mizing drug to protein ratios in order to make formula-
tion of 10 nm BSA-ABZ and 200 nm Nab-ABZ
nanoparticles. Both formulations were examined for cel-
lular uptake and cytotoxicity on ovarian cancer cells
(OVCAR3 and SKOV3) and a human ovarian surface
epithelial cell line (HOSE). Subsequently, we establishedan OVCAR3 xenograft tumor model to evaluate the an-
titumor effects of Nab-ABZ in in vivo. The in-vivo stud-
ies were particularly focused on the measurement of
tumor burden, ascites fluid volume, number of ascites
cells, VEGF and SPARC expression in tumor and VEGF
concentration in plasma. Finally, the objective of this
study was to determine the most effective formulation/
particle size that may provide a rationale to select the
most suitable regimens for subsequent pre-clinical and
clinical evaluations, hopefully in the near future.
Results
Preparation, characterization and drug release
Drug loaded nanoparticles were prepared by a modifica-
tion of the desolvation method as shown in Figure 1A.
ABZ was dissolved in tetrahydrofuran (THF) and subse-
quently mixed with an aqueous solution of albumin
under stirring. The mixture was finally heated up to the
boiling point of THF to remove the solvent from final
preparation. The formulations were prepared with a low
ABZ to protein ratio (1:100) for 10 nm nanoparticles
and (1:5) for 200 nm nanoparticles. Therefore, these for-
mulations do not require any sedimentation by centrifu-
gation to isolate aggregated particles (reaction products)
and then subsequently evade washing steps to achieve
100% drug added in the formulation. Nab-ABZ with a
particle size of 200 nm was synthesized using the same
method with a higher concentration of ABZ in the initial
solution. The nanoparticles were spherical in shape and
possessed a smooth surface morphology as shown
by transmission electron microscope (TEM) (Figure 1B
and C). Dynamic light scattering (DLS) measurements
demonstrated mono-modal particle size distribution for
both nanoparticles (Figure 1D and see Additional file 1).
Considering the size of BSA of around 5 nm, these re-
sults suggest the aggregation of only a few protein mole-
cules in the case of the 10 nm particle. The change of
the nanoparticle synthesis method may change the char-
acteristics of particles [22]. However, there was no sig-
nificant difference in release behaviour between the two
formulations (Figure 2). 50% and 37% of the drug was
released from BSA-ABZ 10 nm and Nab-ABZ 200 nm
respectively in the first 6 hours at pH 7.4. The BSA-ABZ
10 nm reached 93% of accumulated release after 8 days
in comparison to 83% for Nab-ABZ 200 nm. Overall,
our release data showed an initial burst release followed
by a steady release of ABZ for approximately 8 days, in-
dicating that the delivery system was effective for an ex-
tended period of time.
In-vitro cytotoxicity
We assessed the cytotoxicity of BSA-ABZ 10 nm and
Nab-ABZ 200 nm and free ABZ against ovarian cancer
cells (OVCAR3 and SKOV3) and a normal ovarian cell
Figure 1 Synthesis and characterization of nab-ABZ. Schematic illustration of albendazole encapsulation by albumin nanoparticles (A). TEM
images of BSA-ABZ 10 nm (B), the scale bar is 500 nm and TEM images of Nab-ABZ 200 nm (C), and the scale bar is 0.2 μm. Size distribution (volume
%) measured by DLS of BSA-ABZ 10 nm (D) and Nab-ABZ 200 nm (E). Data are presented as the average of two measurements. TEM images confirmed
the particle size of DLS.
Figure 2 Release profile of albendazole from albumin
nanoparticles. In-vitro release behaviour of ABZ from nanoparticle
formulations BSA-ABZ 10 nm and Nab-ABZ 200 nm in PBS at pH 7.4.
The nanoparticle dispersion was placed in an orbital shaker and shaken
at 100 rpm at 37°C for 192 hours. The released ABZ concentration was
measured by HPLC. Data are presented as mean ± SD (n = 2).
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in Figure 3, nab-ABZ 200 nm and free ABZ exhibited a
dose dependent cytotoxicity against ovarian cancer cells
(Figure 3A and B). The BSA-ABZ 10 nm at the lowest
concentration (0.09 μM) significantly inhibited cell pro-
liferation compare to free ABZ and nab-ABZ 200 nm in
both cell lines (OVCAR3 and SKOV3). Interestingly, no
apparent toxicity was observed in HOSE cell line even at
highest dose (1.88 μM). Nearly 20% cell’s proliferation
inhibition was detected by free ABZ at the highest con-
centration in HOSE. Therefore, both formulations were
toxic to the ovarian cells whereas nontoxic to the HOSE
cell which indicated the possibility of targeted thera-
peutic effect against cancer (Figure 3C).
Cellular Internalization
The internalization of BSA-ABZ and Nab-ABZ in
SKOV3 cells was visualized by confocal microscopy and
the intensity of the fluorescent particles was measured
by FACS analysis. The internalization of particles was
depicted in Figure 4A and B for 10 nm and 200 nm re-
spectively. The fluorescent intensity was significantly
Figure 3 Cytotoxicity of albendazole loaded albumin nanoparticles. Comparison of the cytotoxic effects of BSA-ABZ 10 nm, Nab-ABZ 200 nm
and free ABZ in ovarian cancer cells, OVCAR3 (A) SKOV3 (B) and HOSE (C) at different concentration of ABZ (μM) for 72 hours. Each experiment was
conducted three times with replicates of 4 to 8 for each drug concentration. Data are presented as mean ± SD (n = 3).
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compared to 200 nm. Similarly, the uptake of BSA-ABZ
10 nm by SKOV3 cells was more prominent than that of
Nab-ABZ 200 nm as measured by FACS analysis. In fact,
there was no significant increase of fluorescence after
15 minutes incubation suggesting that most of the parti-
cles were taken up within 15 minutes (Figure 4C). Rela-
tive fluorescence intensity was detected at much higher
levels in cells incubated with BSA-ABZ 10 nm compared
to Nab-ABZ 200 nm (Figure 4E). Both FACS and micro-
scopic observations confirmed that higher fluorescence
intensity was detected in the cells incubated with BSA-
ABZ 10 nm compared to Nab-ABZ 200 nm.
In-vivo antitumor effect of ABZ nanoformulations
Antitumor efficacy of nanoparticle formulations was
evaluated in a study using the human OVCAR3 ovarian
cancer xenograft model. The mice were treated intraper-
itoneally with vehicle, free ABZ (50 mg/kg), BSA-ABZ
10 nm where ABZ concentration 10 μg/ml (0.5 mg/kg)
and Nab-ABZ 200 nm where ABZ concentration
200 μg/ml (10 mg/kg). To assure accurate comparison
of tumor burdens, all groups were sacrificed when con-
trol group developed clinical evidence of disease pro-
gression. Intraperitoneal administration of BSA-ABZ
10 nm, three times weekly for 3 weeks led to a signifi-
cant reduction (p < 0.02) in average tumor weight com-
pare to free ABZ (Figure 5A). In contrast, the tumor
weight was not reduced to the same extent when using
Nab-ABZ 200 nm group (Figure 5A). During the experi-
ment, relative body weight and body circumference were
also determined with the change of body weight as an
indicator of toxicity (Figure 5B and C). None of animals
treated with nanoparticles displayed evidence of major
systemic toxicities including weight loss, inability to ob-
tain food or water, hunched appearance, intra-abdominal
adhesion or obstruction.ABZ nanoformulation reduces ascites fluid in peritoneal
cavity
Before euthanasia a peritoneal wash containing ascites
fluid was collected from animals at the end of drug
treatment and the volume was measured. The ascites
volume of both groups was found to be significantly
lower than the control group (free ABZ) (Figure 6A).
The ascites cells were washed with PBS by centrifugation
and counted and found to be significantly lower in the
Nab-ABZ 200 nm group (Figure 6B). Remarkably, one
mouse was detected to be free of ascites in the Nab-ABZ
200 nm group.
ABZ nanoformulation suppresses VEGF in tumor and
plasma of mice-bearing OVCAR3 tumor
To further explore the changes at molecular level,
tumor samples of the animals from each group were
analysed for VEGF expression. Level of VEGF was re-
duced in both formulations (Figure 7A). SPARC is also
correlated with the prognosis of cancer. SPARC expres-
sion was reduced in the Nab-ABZ 200 nm group. In
contrast to the tumor VEGF, the VEGF level in plasma
was not significantly reduced as shown in Figure 7B.
The VEGF level was reduced by 45% in the BSA-ABZ
10 nm and 35% in the Nab-ABZ 200 nm compared to
the control group.
Discussion
The present study was designed to examine the effect of
nanoparticle formulations on the disposition and activity
of IP therapy in ovarian cancer xenograft model. A typ-
ical feature of epithelial ovarian carcinoma is its ten-
dency to metastasize to the peritoneal cavity during
disease progression. Poor drug penetration into the
tumor tissues remains a significant challenge of conven-
tional chemotherapy. Randomized phase III clinical trials
in ovarian carcinoma showed increased overall survival
Figure 4 Internalization of albumin nanoparticles. Internalization of albumin nanoparticles was examined by confocal laser scanning
microscope. SKOV3 cells were incubated with alexa-488 conjugated BSA-ABZ 10 nm (A) and Nab-ABZ 200 nm (B) and the nucleus was stained
with PI (red). The fluorescence intensity and the cell images were obtained using two channels: green λex/ λem = 488 nm/ 492–508 nm for
alexa-488 conjugated BSA NPs and red ( λex/ λem = 568 nm/ 612–622 nm) for the PI. Scale bar is 50 μm and magnification 60Χ with oil immersion
lenses. Cells were treated with fluorescent nanoparticles for 15, 30 and 60 min and uptake of BSA-ABZ 10 nm (C) and Nab-ABZ 200 nm (D) was
quantitatively measured by FACS analysis. Right shift of the chromatogram indicates more cellular uptake (C). Relative fluorescence intensity was
also measured by FACS analysis (E). Data are presented as mean ± SD (n = 2).
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venous chemotherapy [23]. Therefore, we attempted to
examine the effect of intraperitoneal administration of
nanoparticle formulations on tumor growth and ascites
formation in ovarian cancer xenograft model. It has pre-
viously been reported that nanoparticles size < 50 nm are
well absorbed in the peritoneum cavity [24] and easily
pass through the lymph nodes to reach the thoracic
lymph duct and the systemic circulation [25]. Therefore,
one of the objectives of this study was to prepare small
sized nanoparticles which may be well absorbed in the
peritoneum cavity. In addition, these particles released
ABZ slowly over an extended period of time to prevent
the progression of metastasis intraperitoneally.A previous study that focused on the development of
cross-linked albumin nanoparticles for ABZ delivery,
failed to show efficacy in in-vivo (Data not presented). In
our study, we have modified the preparation method
which also changed the hydrodynamic behaviour of par-
ticles as well as their sizes. In-vitro cytotoxicity assay re-
vealed that the BSA-ABZ 10 nm was more toxic to both
ovarian cancer cell lines (OVCAR3 and SKOV3) com-
pared to the Nab-ABZ 200 nm and free ABZ and appar-
ently nontoxic to the ovarian healthy cell (HOSE). The
cellular internalization of alexa-488 conjugated albumin
nanoparticles also demonstrated that both formulations
were readily visible inside the cell membrane. However,
BSA-ABZ 10 nm was more prominent than Nab-ABZ
Figure 5 ABZ nanoformulations lead to enhanced antitumor efficacy in the BALB/c nude mice bearing OVCAR3. Treatment started at day
8 after intraperitoneal injection of OVCAR3 tumor cells at day 0. Vehicle, free ABZ, BSA-ABZ 10 nm and Nab-ABZ 200 nm nanoparticle formulations
were administered on day 8, 11, 14, 17, 20, 23 by intraperitoneal injection in the mice. To compare the fate of nanoparticles in-vivo, different sizes
of particles were administered regardless of particle concentration. A) Tumor weight average B) mice body weight C) mice body circumference
(Mean ± SD, n = 4). Compared to free ABZ, no obvious toxicity observed to the mice which were demonstrated well maintained body weight of
the mice. Three weeks following treatment BSA-ABZ 10 nm animals group reduced tumor burden very significantly (**p < 0.01) and revealed no
evidence of disease, while animals treated with vehicle and free ABZ demonstrated extensive tumor burden. Body weight and abdominal
circumference were measured twice weekly.
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ternalization by quantification of the fluorescent inten-
sity. BSA-ABZ 10 nm showed remarkably higher relative
fluorescent intensity compared to the larger particles
(Figure 4C). The increased cytotoxic effect of BSA-ABZ
10 nm is most likely due to the high ABZ concentration
within the cell owing to higher cellular uptake effi-
ciency. Similar to the in-vitro experiments, the in-
creased antitumor efficacy of BSA-ABZ 10 nm in vivo
may be due to high ABZ concentration in tumors medi-
ated by albumin carrier.
Perhaps, the most important challenge addressed in
this study was the delivery of BSA-ABZ 10 nm and Nab-
ABZ 200 nm in-vivo which led to a superior anti-tumor
activity. A literature search revealed that the in-vivo effi-
cacy of nanoparticles depends on the uptake ofnanoparticles by the tumor with the uptake being in-
creased as particle size decreased [26,27]. Smaller parti-
cles lead to better uptake and therefore, better delivery
of the drug [28] leading to higher toxicity. Nanoparticles
experience more challenges in vivo because of the pres-
ence of variety of proteins and macromolecules that can
degrade nanoparticles , be engulfed by phagocytic cells,
or be taken away from the target site by the lymphatic
system [29]. Therefore, the fate of nanoparticles in the
in vivo setting depends on the degree and pattern of dis-
tribution of nanoparticles, stability, particle size and sur-
face characteristics. In addition, nanoparticles of small
particle diameter (<100 nm) and hydrophilic properties
are capable of avoiding opsonisation and mononuclear
phagocytic system (MPS) degradation resulting in en-
hanced blood circulation time [30,31].
Figure 6 ABZ nanoformulations reduced ascites fluid in peritoneal cavity of female nude mice. Animals were received an IP injection of
OVCAR3 cells in 4 treatment groups. All animals were sacrificed when the tumor controls displayed evidence of disease progression. A) Before sacrifice,
the ascites volume was collected from abdominal cavity and measured. The ascites volume of animal group injected BSA-ABZ 10 nm and Nab-ABZ
200 nm were significantly lower (*P < 0.05) than free ABZ group. B) The ascites cells were washed with PBS and counted and the number of ascites
cells were found to be significantly lower in BSA-ABZ 10 nm (*p < 0.05) and Nab-ABZ 200 nm (**p < 0.01) compare to free ABZ. Each column represents
mean ascites fluid ± SD (n = 4).
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has been reported earlier. ABZ was previously observed to
be well tolerated with a dose at 150 mg/kg, 3 times per
week [11] and 450 mg/kg weekly with combination with
chemotherapeutics [16] in mice model of ovarian cancer
and 2500 mg/day in patients with ovarian cancer [32]. In
the current study, BSA-ABZ 10 nm prevented tumor
growth at ABZ concentration of only 0.5 mg/kg in mice
model. The most interesting observation here is the higher
efficacy in relation to a much lower concentration of ABZ.
The intraperitoneal administration of BSA-ABZ 10 nm
achieves better tumor control compared with Nab-ABZ
200 nm in-vivo although the concentration of ABZ was
extremely low (10 μg/ml). Both formulations were capable
of suppressing ascites volume and Nab-ABZ 200 nm sig-
nificantly reduced ascites cells presented as floating cells
in peritoneal wash. Expression of VEGF was down regu-
lated in both formulations (Figure 7A). VEGF blockade
has previously shown to inhibit ascites formation in sev-
eral mouse model of ovarian cancer and the growth of
solid tumors [33,34]. SPARC expression was significantly
reduced in two mice in Nab-ABZ 200 nm group. Plasma
VEGF concentration was also reduced in both groups
(Figure 7B). In addition, the control mice developed visible
tumor masses with massive ascites fluid, in contrast, mice
treated with nanoparticle formulations showed a remark-
able decrease in ascites production in both formulations
(Figure 7A).
In fact, there are several possible explanations for the
enhanced efficacy of BSA-ABZ 10 nm. Firstly, the albumin
nanocarrier may improve the pharmacokinetic profile ofABZ and prolong its circulation time. These may result in
higher accumulation in tumors due to enhanced perme-
ation and retention (EPR) effects which allows nanoparti-
cles to extravasate through the gaps between the
endothelial cells and accumulate into the tumor tissues
[35]. However, only NPs with specific size ranges can dif-
fuse through the endothelium of tumor tissues and exploit
the EPR effect [36]. The specific size of tumor vasculature
defects depends on the cancer type, tumor site, and dis-
ease stage, but the gap is generally around few nm to
400 nm [37]. NPs must also be larger than 7 nm to avoid
first-pass elimination in the kidney but smaller than
100 nm to avoid being cleared by the liver and spleen
[38,39]. By exploiting albumin pathways, nanoparticles
could transport across the endothelium of blood vessels
via Gp60 and caveolae-mediated transcytosis process and
also by association with the albumin-binding protein
SPARC [19] which may play an important role in the in-
creased tumor accumulation of albumin-bound drugs.
Interestingly, SPARC is overexpressed in several aggressive
cancers and downregulation of SPARC expression de-
creases cancer cell invasion and survival [40].
Secondly, since ABZ nanocarrier accumulates into the
tumor, ABZ was released in a sustained fashion so that
the tumor cells can be exposed to ABZ for a longer
period of time. Thirdly, ABZ nanoparticles have rela-
tively small sizes which may result in deeper penetration
into tumor nodules. These findings highlight the import-
ance of addressing several challenges in intraperitoneal
drug delivery [25]. In addition, intraperitoneal adminis-
tration has been regarded as a site specific delivery to
Figure 7 The expression of VEGF and SPARC in tumor and VEGF in plasma. A) The proteins were extracted from the tumor and concentration
was determined. The expression of VEGF and SPARC was determined by western blot analysis. Tumor from each individual mouse was analysed
separately for VEGF and SPARC levels. GAPDH was used as a control for equal protein loading. B) Following euthanasia, blood was collected by cardiac
puncture and plasma samples were subjected to ELISA assay for VEGF levels. Each column represents mean VEGF levels ± SD (n = 4).
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centration. Possible mechanisms underlying the superior
efficacy of BSA-ABZ 10 nm may be due to compara-
tively higher solubility and the ability to pass through
the extracellular matrix into the tumor whereas
Nab-ABZ 200 nm was probably more localised to the
peritoneal cavity. Both of the formulations are capable of
delivering drug constantly due to their sustained release
profiles. As a result, released ABZ was retained in the
interstitial space of the tumor for a longer period of time
and exerted prolonged tumor abolishing effects in the
peritoneal cavity [41].
Conclusion
The current research shows satisfactory antitumor effi-
cacy of albendazole since albumin nanocarrier was intro-
duced in the formulation. The BSA-ABZ 10 nm is
extremely effective to inhibit the tumor growth with low
dose and Nab-ABZ 200 nm has a good indication for
suppressing VEGF and ascites. However, both of these
possibilities would open new areas of investigation fornanoparticle mediated drug delivery system but require
further analysis of both formulations. Both approaches
have significant benefits and potentials, but are limited
by the access to the tumor which depends on the size of
the particles. Hence, this novel delivery system for ABZ
may provide a solution for the treatment of ovarian can-
cer with peritoneal ascites and overcome short comings
such as adverse toxicities and chemo resistance that re-
sults from current treatment.
Materials and methods
Albendazole, bovine serum albumin (BSA), nile red and
Hydroxypropyl Methycellulose (HPMC) were purchased
from Sigma Aldrich Ltd, Sydney, Australia. All reagents
for cell culture were obtained from Invitrogen, Australia
Pty Ltd. Alexa fluor-488 conjugated BSA was obtained
from Invitrogen, USA. VEGF (sc-7269) mouse monoclo-
nal IgG antibody, SPARC (sc-25574) rabbit polyclonal
IgG antibody, Goat anti-mouse (sc-2031) was purchased
from Santa Cruz Biotechnology. GAPDH (G8795)
mouse monoclonal antibody was purchased from Sigma
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purchased from Cell Signalling.
Preparation, characterization and drug release
Nanoparticle formulations were prepared by a modifica-
tion of the method previously used for the preparation
of cross-linked nanoparticles [42]. In brief, 50 mg (0.1%
BSA) for 10 nm and 500 mg (1% BSA) for 200 nm was
added to 50 ml of aqueous solution under constant stir-
ring (600–800 rpm) at room temperature up to 30 mi-
nutes. After total dissolution, the solution was titrated to
pH 8–9 with 1 N NaOH aqueous solution and stirred
for 30 minutes. ABZ dissolved in THF and added in
0.1% BSA and 1% BSA at 10 μg/ml and 200 μg/ml re-
spectively and stirred up to 4–5 hours to form nanopar-
ticles between size range 8–10 nm and 200–250 nm.
The residual THF was removed by heating up the solu-
tion up to 50–66°C in an oil bath with magnetic stirrer.
Volume was measured and the concentration of ABZ
was determined. Fluorescently labelled nanoparticles
were prepared by using alexa-488 conjugated BSA for
confocal study and nile red was loaded into albumin
nanoparticles for FACS analysis. For animal study ve-
hicle was prepared by making particles without drug
[40]. Free ABZ was prepared as a control by dissolving
ABZ in HPMC [43].
Albumin nanoparticles (0.5–1 mg/ml concentration)
were solubilized in water to determine the particle size
and size distribution by DLS (Malvern Instrument Ltd,
South borough, MA, USA). The morphology of the
nanoparticles was determined by TEM (CM 200, Philips,
USA) using the protocol described previously [42].
Nanoparticle formulations were dissolved in PBS
(pH 7.4) at a concentration of 10 μg / ml (10 nm) and
200 μg /ml (200 nm) and placed in an orbital shaker
(C24 Edison, NJ, USA) at 100 rpm at 37°C for 192 hours
(8 days). At predetermined time point, 500 μl PBS was
collected from each sample and replaced with fresh PBS.
Afterwards the samples were centrifuged at 12,000 rpm
for 20 minutes and collected the supernatant containing
free ABZ and mix with the same volume of methanol to
dissolve ABZ. The concentration of free ABZ was
measured in supernatant using HPLC (LC-20 Series,
Shimadzu, Japan, Class VP software 7.4) and the release
curve was then generated by plotting cumulative ABZ
release versus time. The calculation was performed
based on the equation generated from the calibration
curve prepared from the release standard of ABZ in PBS
and methanol.
Cell culture
Human ovarian cancer cells (SKOV3, OVCAR3) and
HOSE were purchased from American Type Culture
Collection (ATTC, USA) and were maintained at 37°C in5% CO2 in complete media using RPMI 1640 containing
10% (v/v) fetal bovine serum, streptomycin (100 μg/mL),
and penicillin (100 units/mL). HOSE was cultured from
ovarian epithelial cell medium supplemented with
OEPICGS and penicillin streptomycin solution from
ScienCell research laboratories, Carlsbad, CA, USA.
In-vitro cytotoxicity
Cells were seeded into 96-well plates containing 3000
cells/ well and allowed to attach overnight. Once the cells
reached 70% confluence, medium was replaced by serum
free medium containing BSA-ABZ 10 nm, Nab-ABZ
200 nm and free ABZ (ABZ in ethanol) where ABZ con-
centration was 25, 50, 100, 200 and 500 ng/ml equivalent
to 0.09, 0.19, 0.38, 0.75 and 1.88 μM respectively (the mo-
lecular weight of ABZ is 265.33 and BSA is 66.5 KDa).
Equivalent ABZ doses were compared and cells were incu-
bated with the nanoparticles for 72 hours. The cytotoxicity
of ABZ was measured by previously established sulforho-
damine B (SRB) assay [44]. The percentage proliferation of
treatment wells was calculated as absorbance relative to
control wells. The IC50 (the concentration required to de-
crease the cell number by 50%) was determined by using
GraphPad Prism 6 software.
Internalization of ABZ nanoformulation
SKOV3 cells were seeded into 6-well culture plates on
cover slips and treated with BSA-ABZ 10 nm and
Nab-ABZ 200 nm at a particle concentration 500 μg/ml for
2–3 hours. Medium was replaced with serum free RPMI
media before treatment. The cells were washed 2 times
with warm PBS and then fixed with ice cold 70% ethanol in
4°C for 15 minutes and again washed 3 times with cold
PBS to remove ethanol and stained with propidium iodide
(1 mg/ml) for 2 minutes to stain the nucleus. Again the
cells were washed with PBS to remove all unattached stain-
ing. The slides were covered with permount R (oily gelatine)
and closed with cover glasses and placed under the micro-
scope. The nanoparticle distribution was imaged under a
laser scanning microscope (Olympus Fluoview, FV 300,
Japan) with a 60 X objective lens and the images were ana-
lysed using Olympus Fluoview 4.3 software.
For FACS analysis, SKOV3 cells were cultured in a
small flask at a density of 0.8 million cells/flask. After
overnight incubation, the culture medium was replaced
with serum free medium and treated with albumin
nanoparticles at a particle concentration of 500 μg/ml
for 15, 30 and 60 minutes [45]. Fresh medium was used
as a control. Cells were washed with PBS 3 times, trypsi-
nized and centrifuged at 1500 rpm for FACS analysis
using BD FACS Canto IIflow cytometer, USA and ana-
lysed the data using FlowJoV_10 software. The increase
of fluorescence in the cells treated with nanoparticles
relative to that in the untreated control cells expressed
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cles and fluorescent intensity of untreated cells.
Establishment of an ovarian cancer xenograft model
Female athymic nude mice (BALB/c), 8–10 weeks of age
were purchased from the Animal Resources Centre (Perth,
Australia). All animals were housed in a pathogen free en-
vironment according to the guideline of Animal Care and
Ethics Committee of university of New South Wales
(ACEC, UNSW) and all experiments were conducted ac-
cording to the protocols approved by the committee. 16
female nude mice were used for this experiment (Ethic’s
application ID 12/96A) in a project using St George ani-
mal house facility. Animals were received one week earlier
before commencing the experiment.
The pre-cultured OVCAR3 cells were washed with ster-
ile PBS 3 times, centrifuged at 1200 rpm at 4°C for 5 min
to collect tumor cells and then immediately inoculated
into the test animals. Each animal was injected intraperito-
neally 7–10 million tumor cells suspended in PBS.
Drug treatment and sample collection
One week after cell inoculation, mice were randomised
into 4 groups of 4 mice each. Group 1 received vehicle,
group 2, group 3 and group 4 were treated with free ABZ
(50 mg/kg), BSA-ABZ 10 nm (0.5 mg/kg) and Nab-ABZ
200 nm (10 mg/kg) respectively. All groups received the
drug intraperitoneally three times per week and the ex-
periment continued up to 3 weeks. The ascites develop-
ment was noted after 3 weeks and confirmed by
comparison with controls. At the end of the experiment,
the peritoneal cavity was washed with 2 ml of sterile nor-
mal saline and the peritoneal contents were mixed by
kneading and then completely aspirated from each mouse
[16]. Then the mice were sacrificed by an overdose of
Lethabarb (Virbac, Australia) and the tumor weight and
ascites volume was measured. The ascites was collected
after each aspiration and was calculated by deducting 2 ml
from the total volume collected. All visible tumor masses
were carefully collected through laparotomy and the total
mass weight was measured. Dissected tumors and ascites
obtained from each group were all stored at – 80°C for
subsequent analysis.
Western blotting
To produce the lysate from tumor tissue, 100 mg tissue
was lysed and homogenized in radio immuno-
precipitation Assay (RIPA) buffer (Sigma, Australia) con-
taining 10% protease inhibitor cocktail. The samples were
then centrifuged at 10,000 g at 4° C for 10 minutes and
the protein content in supernatant was quantified [17].
Fifty micrograms protein were fixed on 12% gels and elec-
trophoresed for 2 hours at 85 V and transferred to Poly vi-
nylidene Fluoride (PVDF) membranes. The membraneswere incubated with the primary antibodies ( VEGF and
SPARC, 1:200 dilutions, Santa Cruz Biotechnology) for
overnight at 4°C followed by one hour incubation with
secondary antibodies (anti-mouse from Santa Cruz
Biotechnology and anti-rabbit from Cell Signalling, USA).
The bands were visualized by an enhanced chemilumines-
cence detection kit (GE Healthcare, Australia). The blots
were then stripped using Seppro western blot stripping
buffer (Sigma, Australia) and re-probed with GAPDH
(1:1000 dilution, Sigma, Australia).
VEGF ELISA assay
The concentration of VEGF in mice plasma was deter-
mined using Human VEGF Quantikine Enzyme-Linked
Immuno-Sorbent Assay (ELISA) Kit (R&D System) ac-
cording to the manufacturer’s instructions.
Statistical analysis
All statistical analyses were performed using the GraphPad
Prism software package version 6.0 (GraphPad Software
Inc., SanDiego, CA, USA). Data are presented as mean ±
SD duplicate samples from two experiments. Differences
between the groups were evaluated using Student’s t-test
(unpaired) and two tailed p value was applied. P values
(*p < 0.05) and (**p < 0.01) were considered to be statisti-
cally significant and very significant respectively.
Additional file
Additional file 1: (A): Characterization of nab-ABZ 200 nm by
dynamic light scattering (DLS) measurement; size distribution by
number (top) and size distribution by volume (bottom). Polydispersity
index (PDI) of these NPs is 0.12. The result is average of 3 measurements.
(B): Characterization of BSA-ABZ 10 nm by dynamic light scattering (DLS)
measurement; size distribution by volume (top) and size distribution by
number (bottom). Polydispersity index (PDI) of these NPs is 0.19. The
result is average of 3 measurements.
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